Skip to main content


Breast Cancer Research and Treatment

Breast Cancer Research and Treatment OnlineFirst articles

18.01.2019 | Epidemiology

Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors

Venous thromboembolism (VTE), typically manifests as deep vein thrombosis (DVT) and pulmonary embolism (PE), is the second most common cause of death in hospitalized patients with cancer [ 1 – 3 ]. In patients with breast cancer, the VTE prevalence …

18.01.2019 | Epidemiology Open Access

Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant

Breast cancer is a heterogeneous disease consisting of several distinct molecular tumor subtypes significantly differing in prognosis and therapeutic response, namely luminal A, luminal B, HER2-enriched and basal-like [ 1 – 4 ]. These intrinsic …

18.01.2019 | Review

Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials

Women with estrogen receptor-positive (ER+) advanced breast cancer (BC) are usually treated with first-line endocrine therapy unless a visceral crisis or strongly symptomatic metastases exist. CDK4–6 inhibitors (palbociclib, ribociclib, or …

17.01.2019 | Clinical trial

Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience

Resistance to endocrine therapy has been a major hurdle in the management of metastatic oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, leading to treatment failure and progression of …

11.01.2019 | Epidemiology

BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients

BRCA1 / BRCA2 germline mutations are found in up to 5% of breast cancer patients [ 1 ]. Germline mutations in BRCA1 confer a cumulative breast and ovarian cancer risk by age 80 of 72% and 44%, respectively, while BRCA2 mutations represent 69% and …

Aktuelle Ausgaben

Weitere Informationen

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.